TY - JOUR
T1 - The sialic acid-Siglec immune checkpoint
T2 - an opportunity to enhance immune responses and therapy effectiveness in melanoma
AU - Coccimiglio, Magali
AU - Chiodo, Fabrizio
AU - van Kooyk, Yvette
N1 - Publisher Copyright: © The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.
PY - 2024/5
Y1 - 2024/5
N2 - Modulation of immune responses through immune checkpoint blockade has revolutionized cutaneous melanoma treatment. However, it is still the case that not all patients respond successfully to these therapies, indicating the presence of as yet unknown resistance mechanisms. Hence, it is crucial to find novel targets to improve therapy efficacy. One of the described resistance mechanisms is regulated by immune inhibitory Siglec receptors, which are engaged by the carbohydrates sialic acids expressed on tumour cells, contributing to programmed cell death protein-1 (PD1)-like immune suppression mechanisms. In this review, we provide an overview on the regulation of sialic acid synthesis, its expression in melanoma, and the contribution of the sialic acid–Siglec axis to tumour development and immune suppressive mechanisms in the tumour microenvironment. Finally, we highlight potential sialic acid–Siglec axis-related therapeutics to improve the treatment of melanoma.
AB - Modulation of immune responses through immune checkpoint blockade has revolutionized cutaneous melanoma treatment. However, it is still the case that not all patients respond successfully to these therapies, indicating the presence of as yet unknown resistance mechanisms. Hence, it is crucial to find novel targets to improve therapy efficacy. One of the described resistance mechanisms is regulated by immune inhibitory Siglec receptors, which are engaged by the carbohydrates sialic acids expressed on tumour cells, contributing to programmed cell death protein-1 (PD1)-like immune suppression mechanisms. In this review, we provide an overview on the regulation of sialic acid synthesis, its expression in melanoma, and the contribution of the sialic acid–Siglec axis to tumour development and immune suppressive mechanisms in the tumour microenvironment. Finally, we highlight potential sialic acid–Siglec axis-related therapeutics to improve the treatment of melanoma.
UR - http://www.scopus.com/inward/record.url?scp=85190771543&partnerID=8YFLogxK
U2 - 10.1093/bjd/ljad517
DO - 10.1093/bjd/ljad517
M3 - Review article
C2 - 38197441
SN - 0007-0963
VL - 190
SP - 627
EP - 635
JO - British Journal of Dermatology
JF - British Journal of Dermatology
IS - 5
ER -